News

Jim Cramer on Eli Lilly and Company (LLY) – “Buy Hand Over Fist – This GLP-1 Giant Just Crushed Novo”
On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even ...
Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.
Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...
Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills — Update
Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including more than $200 million in upfront and near-term milestone payments.
GSK buys liver drug from Boston Pharmaceuticals for up to $2 billion
GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...
Novo Nordisk Strikes $2.2 Billion Deal With Septerna to Develop New Obesity Treatments
COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...
Why Novo Nordisk (NVO) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom
Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best pharma stocks to invest in now amid the domestic ...
Why Weight-Loss Developer Stocks Tumbled on Tuesday
A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...
One estimate of the profit hit from Trump's executive order on drug pricing
Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...